Entegris Inc vs Intuitive Surgical, Inc. — how do they compare? Entegris Inc trades at $161.64 (market cap $22.95B), while Intuitive Surgical, Inc. trades at $401.04 (market cap $141.75B). The key difference: Intuitive Surgical, Inc. is far larger — about 6.2× Entegris Inc's market cap, and Entegris Inc pays a 0.27% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| ENTG | ISRG | |
|---|---|---|
Market Cap | $22.95B | $141.75B |
Sector | Technology | Health |
52-Week High | $184.00 | $592.85 |
52-Week Low | $68.80 | $332.02 |
Enterprise Value | $26.16B | $136.53B |
Dividend Yield | 0.27% | — |
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $159.66, up 10.71% in 24 hours, reflecting strong momentum driven by Q2 2026 earnings beats and AI-driven semiconductor demand. The stock is near its 52-week high with bullish technical indicators and a consensus price target of $188.67. Revenue growth and margin expansion highlight operational strength, though elevated P/E and P/S ratios signal high valuation expectations.
Outlook is positive with continued earnings growth potential from semiconductor industry tailwinds, but risks include valuation sensitivity and competitive pressures. The stock offers upside to analyst targets but requires monitoring of execution and market volatility.
Intuitive Surgical (ISRG) trades at $403.95, up 2.69% on the day, reflecting strong momentum. The stock exhibits bullish technical signals with support at $398 and resistance at $403. Fundamentally, revenue grew to $10.06B in 2025 with a net income margin of 28.45%, though valuation ratios like a P/E of 46.01 suggest premium pricing. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.80 exceeding expectations. News highlights analyst upgrades and robust adoption of the da Vinci 5 system.
Outlook remains positive driven by innovation and market expansion, but high valuation and competitive pressures pose risks. The consensus price target of $518.10 implies significant upside, supported by 68% buy ratings from analysts. Key risks include reliance on U.S. procedure growth and rising competition from Medtronic and Johnson & Johnson. Long-term growth prospects appear solid if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →